A Study to Evaluate the Association Between BCR-ABL1 Transcript Levels and Progression Free Survival and Event Free Survival in Chronic Myeloid Leukemia (CML) Patients Treated With Imatinib Who Switched Therapy to Dasatinib or Nilotinib

Trial Profile

A Study to Evaluate the Association Between BCR-ABL1 Transcript Levels and Progression Free Survival and Event Free Survival in Chronic Myeloid Leukemia (CML) Patients Treated With Imatinib Who Switched Therapy to Dasatinib or Nilotinib

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2016

At a glance

  • Drugs Dasatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 11 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top